Analysis of 674 Adverse Drug Reaction Reports

Chinese Journal of Pharmacovigilance ›› 2010, Vol. 7 ›› Issue (6): 372-374.

Previous Articles Next Articles

Analysis of 674 Adverse Drug Reaction Reports

BAI Yan-jun¹, JIN Feng², LIU Jing¹, ZHANG Ying¹, YUAN Qiu-ju¹, LI Xin-ling³

1Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China;
2Jilin Center for Drug Reevaluation, JLFDA, Jilin Changchun 130062, China;
3Center for Drug Reevaluation,SFDA, Beijing 100045, China

Received:2016-02-22 Revised:2016-02-22 Online:2010-06-08 Published:2016-02-22

Abstract

Abstract: Objective To study the general pattern and characteristics of adverse drug reaction/event(ADR/ADE) occurred in our hospital for references of rationaI drug use. Methods A total of 674 ADR/ADE cases collected from Janury 2005 to December 2008 were analyzed statistically in respect of patients’ age and sex,drug variet, clinical manifestations,ADR involved organs or systems. Results In the 674 ADR/ADE cases, mainly anti-infective drugs(44.18%), followed by Traditional Chinese Medcines(29.08%). The ADR/ADE were chiefly characterized by the lesions of skin and appen-dants(35.32%). Conclusion The incidence of ADR/ADE can be reduced by strengthening monitoring of ADR and mastering the law of ADR occurrence.

Key words: adverse drug reaction/event, report, analysis

CLC Number:

R994.11

BAI Yan-jun, JIN Feng, LIU Jing, ZHANG Ying, YUAN Qiu-ju, LI Xin-ling. Analysis of 674 Adverse Drug Reaction Reports[J]. Chinese Journal of Pharmacovigilance, 2010, 7(6): 372-374.

[1]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[2]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[3]	WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
[4]	GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
[5]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[6]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[7]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[8]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[9]	YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin. Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
[10]	LIU Qian, HU Jing, LI Bo, YANG Xiaojing. Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
[11]	ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan. Medications of apatinib mesylate in patients with malignant tumors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
[12]	CHANG Yongzhuo, LI Ji, ZHANG Xiaoyan, ZHOU Chaofan. One case of abnormal uterine bleeding caused by Baofukang suppository [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 935-938.
[13]	MENG Kangkang, LIU Saiyue. After-marketing safety of coenzyme Q10 for injection [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 795-798.
[14]	ZHANG Lei, LYU Jian, XIE Yanming. Efficacy and safety of Houpupaiqi Mixture in the treatment of postoperative lieus: a Meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 799-806.
[15]	LIU Jingjing, DAI Zhong, YANG Jianbo, WANG Ying, XU Beilei, LIU Yue, WANG Qi, MA Shuangcheng. Spectrum-fect relationship of Ginseng Radix et Rhizoma Rubra and Polygonum Multiflorum Radix Preparata medicinal pair in protection of nerve cells [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 623-628.

Analysis of 674 Adverse Drug Reaction Reports

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics